Introduction
============

Cellular aging is a state of irreversible cell cycle arrest and actively contribute to degenerative pathologies and somatic senescence. Emerging evidence documents cellular aging associated with some medical and psychiatric conditions including cardiovascular disease, diabetes, neurodegenerative diseases, SCZ and some other psychotic disorders[@b1][@b2][@b3][@b4][@b5]. Telomere erosion and mitochondrial dysfunction are two well-known molecular pathways implicated in the key process of cellular aging. Telomeres are tandem repeats of the sequence TTAGGG at the end of eukaryotic linear chromosomes; they enable chromosome ends to be distinguished from sticky double-stranded breaks and protect the chromosomes from natural cellular degradation and end-to-end fusion[@b6][@b7]. In normal somatic cells, telomeres progressively shorten with each cell division because of the replication problem for the ends of linear DNA and the down-regulated activity of telomerase with limited ability to counteract the eroded strand. When the length of telomere reaches critically short, the cell begins its senescence and apoptosis[@b8]. Thus, telomere length may serve as a biological time recorder to indicate the replicative capacity of a cell along its division.

Mitochondria are key organelles of the eukaryotic cells and carry essential functions in energy metabolism, calcium homeostasis and apoptosis[@b9]. In addition, mitochondria are also the major intracellular source for generation of reactive oxygen species (ROS) and the primary target of ROS-induced oxidative damage[@b10]. In mitochondria, mitochondrial DNA (mtDNA) is highly susceptible to oxidative damage due to high levels of cellular ROS, lack of protective histones and limited DNA repair capacity[@b11][@b12][@b13]. In most cases, the content of mtDNA accurately modulated during physiological processes. However, abnormal variation may occur when the mitochondrial microenvironment was changed. The alteration of mtDNA copy number has been suggested as a sensitive index of cellular oxidative stress, mitochondrial dysfunction, aging process and age-related diseases[@b14].

Recent studies have revealed shared pathways in modulating telomere length and mitochondrial biogenesis[@b15][@b16]. Telomere dysfunction activates p53-mediated pathway to repress the expression of peroxisome proliferator-activated receptor gamma, coactivator 1 alpha and beta (PGC-1α and PGC-1)[@b15]. The repression of both co-activators impairs functional mitochondrial biogenesis leading to increased levels of ROS damaging both telomere and mitochondrial DNA, and starts a negative feedback loop. In addition, telomerase reverse transcriptase (TERT) serves as a catalytic subunit of telomerase with canonical role of telomere maintenance. TERT contains both nuclear localization signal and mitochondrial targeting sequence, and might be transported from nuclei to mitochondria under increased oxidative stress conditions to regulate mitochondrial function and protect mtDNA from oxidative damage[@b17]. Moreover, several studies reported lately that positive correlations have been observed between telomere length and mtDNA copy number variations in healthy adults[@b18][@b19].

Emerging evidence indicates that physiological changes may relate to premature aging that happens in SCZ, and it is tempting to speculate that SCZ might be a syndrome of accelerated aging[@b20]. Given the intimate link between telomere-mediated and mitochondria-mediated pathways and the aging processes, it assumes that the alterations of telomere length and mitochondrial DNA copy number might implicate in SCZ. Several studies have evaluated the influence of telomere length and mtDNA copy number on SCZ[@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30]. However, results are controversial to each other due to the high heterogeneity of SCZ subjects. It has been suggested that antipsychotic treatment may lengthen telomere and affect the function of mitochondrial in SCZ patients. Several cross-sectional studies showed that patients with longer telomere tend to better respond to antipsychotic treatment[@b25][@b31]. On the other hand, treatment responsive SCZ subjects had fewer mitochondria per synapse in striatum[@b32]. Therefore, we hypothesize that: (1) accelerated telomere erosion and mtDNA copy number variations may be associated in first-episode antipsychotic-naive SCZ; (2) antipsychotics may have influence on both telomere and mtDNA; (3) the telomere length and mtDNA copy number may be used to predict if a first-episode SCZ patient be antipsychotic-responsive or not.

In this study, we test our hypothesis with a longitudinal design. We measured the telomere length and mtDNA copy number in first-episode antipsychotic-naïve SCZ patients followed by a 8-week risperidone treatment, and examined whether those two parameters were associated with the treatment-resistant character in SCZ patients.

Results
=======

A total of 137 first-episode antipsychotic-naïve SCZ patients and 144 healthy controls were recruited in this study. [Table 1](#t1){ref-type="table"} presents the demographic data of SCZ patients at baseline and healthy controls. Comparisons of baseline telomere length and mtDNA copy numbers in SCZ group with that in control group were shown in [Fig. 1(A](#f1){ref-type="fig"},B). We observed significant lower baseline mtDNA copy numbers in SCZ patients compared with that in health controls (β = −0.108, p = 0.002). However, the telomere length showed no significant difference between the SCZ and control groups (β = 0.010, p = 0.718). Linear regression analysis showed that sex has no significant effect on telomere length and mtDNA copy numbers over all samples ([Table 2](#t2){ref-type="table"}). However, male SCZ patients demonstrated significant lower mtDNA copy numbers compared with healthy controls, while female patients only showed milder decreased mtDNA copy numbers ([Fig. 1](#f1){ref-type="fig"}D,F). We detected no significant differences in terms of telomere length when compare SCZ patients and controls in sex-stratified analyses ([Fig. 1](#f1){ref-type="fig"}C,E). Age was inversely associated with telomere length and mtDNA copy number (β = −0.007, p = 0.002; β = −0.006, p = 0.031) in all subjects ([Table 2](#t2){ref-type="table"}). In addition, similar trends were observed in control group, but not in SCZ group ([Fig. 2](#f2){ref-type="fig"}). Pearson correlation analysis found a significant correlation between the mtDNA copy number and telomere length (r = 0.200, p = 0.016) in controls, but not in SCZ patients (r = −0.003, p = 0.972).

At the endpoint of 8 weeks, a clinical follow-up was completed on 89 patients to evaluate clinical improvement, and a subset of 83 patients also repeated the biomarker measurements. Using the above-mentioned diagnostic criteria, 46 patients were classified as Responders and 43 as No-Responders. There were no significant differences in PANSS positive symptoms (25.52 ± 4.92 vs 24.47 ± 4.39, p = 0.289), PANSS negative symptoms (21.35 ± 6.47 vs 19.21 ± 5.98, p = 0.110), and PANSS general symptoms (46.43 ± 8.56 vs 47.16 ± 8.21, p = 0.684) at baseline between Responders and No-Responders.

We found that Responders had significantly lower mtDNA copy numbers (β = −0.178, p = 0.001), and milder longer telomere length (β = 0.111, p = 0.071) when compared with No-Responders ([Fig. 1](#f1){ref-type="fig"}G,H). Repeated measures ANOVAs showed a significant group effect for the mtDNA copy number (partial η^2^ = 0.125, p = 0.001), indicating that Responders, compared with Non-Responders, showed persistent lower mtDNA copy numbers across the 2 time points. In contrast, no significant group effect for the telomere length was observed (partial η^2^ = 0.033, p = 0.101). There was no time effect on mtDNA copy number (partial η^2^ = 0.032, p = 0.107) and telomere length (partial η^2^ = 0.013, p = 0.316), with no group by time interaction (p = 0.466 and p = 0.816, respectively), indicating no significant antipsychotic effects on mtDNA copy number and telomere length in the 2 groups of patients.

We also performed exploratory analyses of the relationship between baseline telomere length and mtDNA copy number, and symptom severity and symptom improvement in patients. We found that symptom severity was not significantly correlated with the mtDNA copy numbers and telomere length in SCZ patients ([Table 3](#t3){ref-type="table"}). In addition, multiple linear regression analyses showed that clinical improvement was positively correlated with the baseline telomere length (β = 0.194, p = 0.045) and negatively correlated with the baseline mtDNA copy number (β = −0.267, p = 0.007), indicating that longer telomere length and lower mitDNA copy number at baseline are associated with better symptoms improvement in patients.

Discussion
==========

In this study, our results show markedly lower mtDNA copy numbers in SCZ compared with healthy controls, indicating a potential role for mitochondrial impairment in the pathogenic pathways of SCZ. This finding is bolstered by prior similar studies for significantly decreased mitochondrial number in brain tissues and peripheral lymphocytes[@b33][@b34][@b35]. However two previous postmortem studies reported no anomalous mtDNA copy number in brain tissues of SCZ[@b28][@b29]. Several possibilities might explain the above inconsistency. One explanation is that the mtDNA copy number was measured in different tissues cells, which may influence the outcomes. Another possible explanation is that agonal duration as a confounder may conceal the indigenous alteration of mtDNA in postmortem studies[@b36]. Finally, we cannot exclude the possibility that the discrepancy may be caused by sample size. We tested 281 subjects whereas the previous studies have relatively smaller sample size (30 and 89 subjects, respectively).

Many studies reported short telomere length in SCZ[@b21][@b25][@b26][@b30]. However, several other studies failed to replicate this finding[@b22][@b23][@b24]. In our study, we did not find any alteration of telomere length in first-episode antipsychotic-naïve SCZ when compared with healthy subjects. Some confounders including illness duration, age of subjects, lifestyle and antipsychotics use might partly explain these conflicting results. Alternatively, reduced telomere length may not be an intrinsic feature of mental disorders but a result of cumulative exposure to chronic stress[@b37][@b38]. In this sense, telomere erosion may be mild in early-phase SCZ, since these individuals undergoing short-term exposure to stress. Therefore, we cannot exclude the possibility that the stress-mediated telomere erosion might be too tiny to be detected in our patients because they had much younger age and shorter illness duration than the patients in previous studies.

Consistent with previous studies, our data in control population showed a strong association between telomere length and mtDNA copy number, and further supports a shared pathway in governing telomere and mitochondrial biogenesis in cellar aging[@b18][@b19]. However, this association was not observed in SCZ group implying that the pathways shared by regulating telomere length and mitochondrial biogenesis might be disturbed by the pathophysiology of SCZ.

The intriguing findings of this study show that telomere length and mtDNA copy number at baseline may predict risperidone treatment response or clinical improvement at the 8 weeks follow-up in first-episode antipsychotic-naive SCZ patients. Although the molecular mechanism linking telomere and mitochondria to schizophrenic symptom is poorly understood, several cross-sectional studies have suggested that telomere length and mitochondria number might be associated with antipsychotic response in SCZ[@b25][@b32]. Evidence supported that patients with severer initial illness may be better treated by antipsychotics[@b39]. Therefore, we hypothesized that patients with longer telomere or lower mtDNA copy number may have severer schizophrenic symptom, and this may indicate better clinical improvement. However, this interpretation is not supported by our data. Our results showed that neither telomere length nor mtDNA copy number were significantly associated with the symptom severity of SCZ. Further studies are needed to illuminate the roles and mechanisms of telomere and mitochondria in the psychopharmacology and pathogenesis in SCZ.

Several limitations need to be acknowledged. First, 8 weeks of risperidone treatment was relative short to detect the antipsychotic effect on the longitudinal changes of telomere length and mtDNA copy number in SCZ Patients. The limited statistical power may explain the discrepancy between our results and previous studies that suggested risperidone having an adverse effect on mitochondria and a protective effect on telomere[@b40][@b41][@b42]. Second, we only measured here the telomere length and mtDNA copy number; more studies may help by investigating the association between telomerase activity or mitochondrial electron transport chain (ETC) enzyme activities and the treatment response of SCZ patients.

In conclusion, our study showed that patients with first-episode antipsychotic-naïve SCZ may be associated with mitochondria, but not telomere. Interestingly, our data suggest that telomere length and mtDNA copy number in patients at baseline hold the potential to predict the effectiveness of risperidone treatment. Although the exact pathways of our finding remains unclear and requires further exploration, it may shed light on the understanding of psychopharmacological mechanism of SCZ.

Methods
=======

Participants
------------

First-episode antipsychotic-naïve SCZ patients were recruited from the Second Affiliated Hospital of Xinxiang Medical University and the Third People's Hospital of Yichun. Patients were diagnosed as first-episode SCZ according to the criteria of DSM-IV and were never treated with antipsychotic medications or other psychotropics. The diagnosis of SCZ was further evaluated by a clinical psychiatrist based on the Structured Clinical Interview for DSM- IV Axis I Disorders (SCID-IV). The symptoms of SCZ were assessed by using the Positive and Negative Symptom Scale (PANSS). The exclusion criteria for patients included: any other Axis I Disorders (depression, bipolar disorder, and substance abuse) and any Axis II Disorders; prior antipsychotic treatment; history of serious medical or neurological disorders; family history of mental or neurological disorders; current serious medical disorders, such as cancer, cardiovascular diseases and neurological disorders. Healthy controls were recruited from the local community through advertisement. Current mental status, substance use, history of physical or neurological illness and personal or family history of any mental disorder for all healthy subjects were assessed by unstructured interviews. Subjects with history of mental or neurological disorders, current substance use and serious medical disorders were excluded from the study.

The complete details of the entire study design and procedures were in accordance with the Declaration of Helsinki. Written informed consent was obtained from each participant and consent from each participant's guardian was also obtained. This study was approved by the ethics committee of the Second Xiangya Hospital of Central South University.

Medication and clinical assessments
-----------------------------------

All patients took risperidone monotherapy for 8 weeks. The dose of antipsychotic was decided by the attending psychiatrist according to the clinical status of patients. Compliance with risperidone was monitored by clinical interviews once two week. No serious side effects were reported during the treatment. Psychopathological status of patients was assessed by using the PANSS at baseline and endpoint of 8-week treatment. The percentage of clinical improvement at 8 weeks was calculated using the formula P% = \[(P~0~--P~1~)/P~0~\] × 100, where P~0~ was PANSS total score at baseline and P~1~ was 8-week follow-up PANSS total score. According to Leucht *et al.* and Obermeier *et al.* PANSS total score were corrected by subtracting 30 points (the minimum value of PANSS scale) to every PANSS ratings before calculating percentage of clinical improvement[@b43][@b44]. In this study, the treatment response threshold was defined as the percentage of PANSS reduction above 50%.

Measurement of telomere length and mtDNA copy number
----------------------------------------------------

Peripheral blood samples (5 ml) were collected in EDTA tubes and kept at −70 °C before use. Genomic DNA was isolated from 200 μl of each blood sample using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and according to the manufacturer's protocol. DNA samples were quantified using the Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

The telomere length was measured by quantitative polymerase chain reaction (qPCR) originally described by Cawthon[@b45]. Briefly, the qPCR was assayed by using Maxima SYBR Green qPCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA). The primers for the telomere PCR were 270 nM Tel1 (5′-GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT-3′) and 900 nM Tel2 (5′-TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA-3′) and for single-copy gene (36B4) PCR were 300 nM 36B4u (5′-CAGCAAGTGGGAAGGTGTAATCC-3′) and 500 nM 36B4d (5′-CCCATTCTATCATCAACGGGTACAA-3′)[@b45]. The profile of the telomere amplification was 95 °C for 10 min followed by 30 cycles of 95 °C for 15 seconds, 54 °C for 2 minutes. The profile of the 36B4 amplification was 95 °C for 10 min followed by 35 cycles of 95 °C for 15 seconds and 58 °C for 1 minute.

The mtDNA copy number was assayed by using LightCycler® 480 SYBR Green I Master (Roche, Manheim, Germany). The primers for the mtDNA copy number were 200 nM ND1-F (5′-CCCTAAAACCCGCCACATCT-3′) and 200 nM ND1-R (5′-GAGCGATGGTGAGAGCTA- AGGT-3′). The primers for nuclear single-copy gene (HGB) were 167 nM HGB-F (5′-GTGCACCTGACTCCTGAGGAGA-3′) and 167 nM HGB-R (5′-CCTTGATACCAACCTG- CCCAG-3′)[@b46]. The thermal cycler condition of the ND1 gene amplification was 95 °C for 10 min followed by 30 cycles of 95 °C for 15 seconds, 60 °C for 1 minute. The thermal cycler condition of the HGB gene amplification was 95 °C for 10 min followed by 35 cycles of 95 °C for 15 seconds, 56 °C for 1 minute.

All qPCR were performed on a Roche LightCycler® 480 machine (Roche Applied Science, Mannhein, Germany). Each sample was run in triplicate using 10 ng DNA per 10 μl reaction. The targeted gene (Tel, ND1) and single copy gene (36B4, HGB) PCR reactions were carried out on separate runs with the same samples in the same well positions, and melting curve analysis was performed for every run to verify specificity. The measures of telomere length and mtDNA copy number were determined by the ratio of telomere and mtDNA content to a reference single copy gene copy number (T/S ratio) in each sample relative to a reference sample. The T and S values were determined by the standard curve method using a serially diluted reference DNA (five point) and the T/S ratio was derived from the T and S value for each sample.

**S**tatistical analysis
------------------------

All analyses were performed using the Statistical Package for Social Sciences (SPSS, version 20.0 for Windows). Telomere length was natural transformed to adjust for skewed distributions prior to analysis. Demographic characteristics of the SCZ and control groups were compared using chi squared test or Fisher exact test for categorical variables and independent Student's t-test for continuous variables. Multiple linear regression analysis was applied to analyzed between-group comparisons in telomere length and mtDNA copy number with age and gender as covariates. Repeated measures ANOVAs were performed to test longitudinal within-group changes (Responders and Non-Responders), and group×time (baseline and follow-up) interaction for telomere length and mtDNA copy number. All P-values were two-sided and considered statistically significant at α \< 0.05.
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###### Demographic and clinical variables for the subjects.

  Variables                       Schizophrenia (N = 137)   Healthy control (N = 144)   P value
  ------------------------------ ------------------------- --------------------------- ---------
  Age (years)                          25.46 ± 7.27               26.03 ± 5.19           0.452
  Sex (M/F)                                95/42                      87/57              0.118
  Illness of duration (months)         9.80 ± 12.58                                         
  Positive syndromes                   24.54 ± 4.80                                    
  Negative syndromes                   20.96 ± 6.62                                    
  General syndromes                    45.79 ± 8.33                                    

###### Linear regression analyses of natural transformed telomere length and mtDNA copy number in schizophrenia patients and controls.

  Parameter                  Natural transformed telomere length   MtDNA copy number                               
  ------------------------- ------------------------------------- ------------------- ----------- -------- ------- -------------
  Overall                                                                                                          
   **Intercept**                            0.184                        0.080           0.022     1.184    0.101   **\<0.001**
   **Patient vs control**                   0.010                        0.027           0.718     −0.108   0.034    **0.002**
   **Female vs Male**                       0.018                        0.028           0.507     0.057    0.035      0.105
   **Age**                                 −0.007                        0.002         **0.002**   −0.006   0.003    **0.031**

Bold value indicates significant result (P\<0.05).

###### Correlation of telomere length and mitochondrial DNA copy number with between symptoms severity at baseline in schizophrenia. All models were adjusted for age, gender, illness duration.

  Variables                Baseline natural transformed telomere length   Baseline mtDNA copy number           
  ----------------------- ---------------------------------------------- ---------------------------- -------- -------
  PANSS subscales                                                                                              
   Positive syndromes                         0.411                                 0.818              −3.389   0.069
   Negative syndromes                         −0.439                                0.855              −1.800   0.477
   General syndromes                          0.252                                 0.935              −0.026   0.993
  PANSS total syndromes                       0.224                                 0.967              −5.215   0.357
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